Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe.
Testicular germ cell tumors are the most commonly diagnosed cancers, and surgical removal of the testes
is often a radical necessity along with chemotherapy and radiotherapy. While seminomas are receptive
to radiotherapy as well as chemotherapy, non-seminomatous germ cell tumors respond to chemotherapy
only. Due to the singular nature of testicular cancers with associated orchiectomy and mortality,
it is important to study the molecular basis and genetic underpinnings of this group of cancers across
male populations globally. In this review, we shed light on the population pharmacogenetics of testicular
cancer, pediatric and adult tumors, current clinical trials, genetic determinants of chemotherapy-induced
toxicity in testicular cancer, as well as the molecular signal transduction pathways operating in this malignancy.
Taken together, our discussions will help in enhancing our understanding of genetic factors in
testicular carcinogenesis and chemotherapy-induced toxicity, augment our knowledge of this aggressive
cancer at the cellular and molecular level, as well as improve precision medicine approaches to combat
Keywords: Variant polymorphism, Pharmacogenetics, Population pharmacogenetics, Precision medicine, Testicular seminoma,
Testicular cancer, Ethnicity, Pharmacogenomics, Toxicity, Clinical trials, Molecular aspects, Signal transduction.
Rights & PermissionsPrintExport